Ryvu and nCage Partner on ADCs

Ryvu Therapeutics and nCage Therapeutics have initiated a research partnership to create an advanced antibody-drug conjugate (ADC) platform using nCage’s innovative TRAP cage technology. The TRAP cage platform includes virus-like particles designed to transport therapeutic molecules directly into target cells, aiming to enhance ADCs’ safety and efficacy. By improving the antibody-to-drug ratio (DAR), this collaboration hopes to lessen toxicity and widen treatment options for patients. This alliance marks a strategic step for both companies in developing safer oncology therapies through next-generation ADCs.

nCage’s CEO, John Bason, expressed optimism about broadening the company’s reach by integrating Ryvu’s expertise with their own, which has already shown promise in vaccine development. Ryvu’s Chief Scientific Officer, Krzysztof Brzózka, emphasized the collaboration as an opportunity to pair their small molecule expertise with nCage's novel delivery platform to advance cancer treatment options. Both Ryvu and nCage will individually cover their costs in this partnership and will jointly own the data generated, underscoring their commitment to developing ADC technologies that offer more effective and safer therapeutic solutions.